180 related articles for article (PubMed ID: 26018688)
1. Prostate-Specific Membrane Antigen PET/CT in Splenic Sarcoidosis.
Kobe C; Maintz D; Fischer T; Drzezga A; Chang DH
Clin Nucl Med; 2015 Nov; 40(11):897-8. PubMed ID: 26018688
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
4. Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT.
Lawal I; Vorster M; Boshomane T; Ololade K; Ebenhan T; Sathekge M
Clin Nucl Med; 2015 Sep; 40(9):755-6. PubMed ID: 26053729
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-PSMA PET/MR-Positive, Histopathology-Proven Prostate Cancer in a Patient With Negative Multiparametric Prostate MRI.
Muehlematter UJ; Rupp NJ; Mueller J; Eberli D; Burger IA
Clin Nucl Med; 2018 Aug; 43(8):e282-e284. PubMed ID: 29847319
[TBL] [Abstract][Full Text] [Related]
6. Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.
Yilmaz B; Turkay R; Colakoglu Y; Baytekin HF; Ergul N; Sahin S; Tugcu V; Inci E; Tasci AI; Cermik TF
Prostate; 2019 Jun; 79(9):1007-1017. PubMed ID: 31012125
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
8. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.
Freitag MT; Radtke JP; Hadaschik BA; Kopp-Schneider A; Eder M; Kopka K; Haberkorn U; Roethke M; Schlemmer HP; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):70-83. PubMed ID: 26508290
[TBL] [Abstract][Full Text] [Related]
9. Clinical performance of
Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.
Afshar-Oromieh A; Avtzi E; Giesel FL; Holland-Letz T; Linhart HG; Eder M; Eisenhut M; Boxler S; Hadaschik BA; Kratochwil C; Weichert W; Kopka K; Debus J; Haberkorn U
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):197-209. PubMed ID: 25411132
[TBL] [Abstract][Full Text] [Related]
11. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy.
Rauscher I; Maurer T; Beer AJ; Graner FP; Haller B; Weirich G; Doherty A; Gschwend JE; Schwaiger M; Eiber M
J Nucl Med; 2016 Nov; 57(11):1713-1719. PubMed ID: 27261524
[TBL] [Abstract][Full Text] [Related]
12. [(68)Ga-PSMA as a new tracer for evaluation of prostate cancer: comparison between PET-CT and PET-MRI in biochemical recurrence].
Avanesov M; Karul M; Derlin T
Radiologe; 2015 Feb; 55(2):89-91. PubMed ID: 25583413
[No Abstract] [Full Text] [Related]
13. Detection Rate and Localization of Prostate Cancer Recurrence Using
Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
[TBL] [Abstract][Full Text] [Related]
14. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
Lin CY; Lee MT; Lin CL; Kao CH
Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
[TBL] [Abstract][Full Text] [Related]
15. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of
Scholte M; Barentsz JO; Sedelaar JPM; Gotthardt M; Grutters JPC; Rovers MM
Eur Urol Focus; 2020 Sep; 6(5):967-974. PubMed ID: 30826284
[TBL] [Abstract][Full Text] [Related]
16. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?
Kulkarni SC; Sundaram PS; Padma S
Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366
[TBL] [Abstract][Full Text] [Related]
17.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.
Afshar-Oromieh A; Haberkorn U; Schlemmer HP; Fenchel M; Eder M; Eisenhut M; Hadaschik BA; Kopp-Schneider A; Röthke M
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):887-97. PubMed ID: 24352789
[TBL] [Abstract][Full Text] [Related]
19. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
20. Nuclear Medicine Imaging of Prostate Cancer.
Schreiter V; Reimann C; Geisel D; Schreiter NF
Rofo; 2016 Nov; 188(11):1037-1044. PubMed ID: 27299668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
